      Document 0032
 DOCN  DRG0032
 UNIQUE IDENTIFIER        DRG-0215
 NAME OF SUBSTANCE        935U83 [FDA 237A]
 SYNONYMS                 5-Chloro-2',3'-dideoxy-3'-flourouridine
                          [Antimicrob Agents Chemother 1994 Jul;38(7)]
 PROTOCOL ID NUMBERS      FDA 237A
 SECONDARY SOURCE ID      DRG
 DISEASES STUDIED/TREATED Primary HIV infection [FDA 237A]
 DISEASES STUDIED/TREATED Drug development discontinued per company
                          [Glaxo Wellcome 4/96]
 CLASSIFICATION CODE      Antiretroviral [FDA 237A]
 CONTRAINDICATIONS        Contraindicated in pregnant women. [FDA 237A]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: A 3'-fluoropyrimidine
                          nucleoside [Antimicrob Agebts Chemother 1994
                          Jul;38(7)]
 SUBSTANCE DELIVERY DATA  MODE OF DELIVERY: Oral. [FDA 237A]
 MANUFACTURERS            Glaxo Wellcome
 REFERENCES               Bartlett JA, McMahon D. A phase I trial of
                          BW935U83 in HIV infected persons. Natl Conf
                          Hum Retroviruses Relat Infect (2nd). 1995 Jan
                          29-Feb 2;:104.
 REFERENCES               Joyner SS, Novak P, Dornsife RE, Dev IK.
                          Molecular basis for the increased
                          hematopoietic toxicity of FLT compared to AZT
                          and 935U83. Program Abstr Intersci Conf
                          Antimicrob Agents Chemother. 1994 Oct
                          4-7;:93.
 REFERENCES               Bartlett JA, Fife KH. A phase I trial of
                          BW935U83 in HIV infected persons. Program
                          Abstr Intersci Conf Antimicrob Agents
                          Chemother. 1994 Oct 4-7;:133.
 REFERENCES               Daluge SM, Purifoy DJ, Savina PM, St Clair
                          MH, Parry NR, Dev IK, Novak P, Ayers KM,
                          Reardon JE, Roberts GB, et al.
                          5-Chloro-2',3'-dideoxy-3'-fluorouridine
                          (935U83), a selective anti-human
                          immunodeficiency virus agent with an improved
                          metabolic and toxicological profile.
                          Antimicrob Agents Chemother. 1994
                          Jul;38(7):1590-603.
 REFERENCES               Riddler SA, McMahon DK, Bartlett JA, Savina
                          PM, Wang LH, Dunn JA, Mellors JW. A phase I
                          single-dose trial to evaluate the safety and
                          pharmacokinetics (PK) of
                          5-chloro-2'3'-dideoxy-3'flourouridine
                          (935U83). Natl Conf Hum Retroviruses Relat
                          Infect (1st). 1993 Dec 12-16;:160.
 ENTRY MONTH              9408
 LAST REVISION DATE       960612
 

SOURCE: National Library of Medicine, Bethesda, MD.  Distributed by AEGIS.
